ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 41

Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity

Peter Schafer1, Emily Rychak2, Derek Mendy3, Stacey Parton1, Lori Capone4, Antonia Lopez-Girona2, Dorota Cedzik5, Jolanta Kosek5, Ling-Hua Zhang5 and Rajesh Chopra5, 1Department of Translational Development, Celgene Corporation, Summit, NJ, 2Molecular & Medical Science, Celgene Signal Research, San Diego, CA, 3Celgene Signal Research, San Diego, CA, 4Celgene Corporation, Summit, NJ, 5Translational Development, Celgene Corporation, Summit, NJ

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, SLE, T cells and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Session Title: B cell Function and Targeting in Systemic Lupus Erythematosus

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex including CUL4A, DDB1, and ROC-1. CC-220 is a novel immunomodulatory compound currently in development for the treatment of immune conditions. The effects of CC-220 on CRBN binding and ubiquitination, and on immune cell responses were profiled.

Methods: Binding studies to CRBN were conducted using endogenous CRBN from human U266 plasmacytoma cells and affinity beads in a competition assay by quantitative immunoblot determination. CRBN ubiquitination was measured in HEK293T cells transfected with a His-biotin-tagged CRBN construct, treated with the MG132 proteasome inhibitor (to arrest degradation of ubiquitinated proteins). Cells were lysed and processed to measure CRBN ubiquitination by SDS-PAGE and immunoblot analysis. T-cell costimulation was measured in purified primary human T cells stimulated using immobilized anti-CD3 antibody. Cytokine secretion was measured by ELISA. Immunoglobulin M and G (IgG and IgM) production was measured from normal donor peripheral blood mononuclear cells by culturing in the presence of the B cell differentiation factors IL-2, IL-6, IL-10, IL-15, CD40L, and TLR9 ligand. IgM and IgG were measured by ELISA. Cell proliferation studies were conducted in H929 plasmacytoma cells assessed by 7-aminoactinomycin D (7-AAD) staining. Toll-like Receptor 4 (TLR4) stimulation was performed in human PBMC from subjects with SLE and SSc using lipopolysaccharide (LPS).

Results: In the competitive CRBN binding studies, CC-220 had a 50% inhibitory concentration (IC50) of approximately 0.1 μM, compared with 3 μM for pomalidomide. CRBN ubiquitination studies in the transfected HEK293T cells resulted in an IC50 of 0.19 μM. CC-220 costimulated IL-2 production by T cells with an EC50 of approximately 0.29 nM, compared with 10 nM for pomalidomide. CC-220 inhibited IgM and IgG production with an IC50 of 0.35 and 2.1 nM, respectively, compared to 17 nM and 63 nM for pomalidomide. The IC50 value for inhibition of proliferation by CC-220 was 0.01 μM in the H929 plasmacytoma cell line. A 50% decrease in cell cycle (S-phase) was evident after 24 hours of treatment of H929 cells with CC-220. At 48 hours, CC-220 decreased expression of survivin and retinoblastoma protein (pRB) and increased expression of the cyclin-dependent kinase inhibitor p27. In LPS-stimulated PBMC from systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) patients, CC-220 significantly reduced production of pro-inflammatory cytokines including TNF-α, IL-1α, IL-1β, and IL-6, and increased production of IL-10.

Conclusion: The results indicate that CC-220 binds to CRBN and inhibits CRBN ubiquitination CC-220 enhances T cell IL-2 production, but inhibits B cell production of immunoglobulin and reduces plasma cell line proliferation. This compound also reduces the production of several key inflammatory mediators by SLE and SSc patients cells stimulated via the TLR4 pathway. In summary, CC-220 is a novel high affinity CRBN ligand with immunomodulatory effects and is currently in development for the treatment of immune and inflammatory diseases.


Disclosure:

P. Schafer,

Celgene,

3;

E. Rychak,

Celgene,

3;

D. Mendy,

Celgene,

3,

Celgene,

1;

S. Parton,

Celgene,

3;

L. Capone,

Celgene,

3;

A. Lopez-Girona,

Celgene,

3;

D. Cedzik,

Celgene,

3;

J. Kosek,

Celgene,

3;

L. H. Zhang,

Celgene,

3;

R. Chopra,

Celgene,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-cereblon-with-the-high-affinity-immunomodulatory-compound-cc-220-a-novel-therapeutic-agent-for-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences